

Remarks


Applicants elect the invention of Group II, claims 11-12, drawn to a method of treating cancer such as Hodgkins' Disease, Non-Hodgkins' Lymphoma, neuroblastoma, breast, ovarian, etc., comprising administering to a mammal a therapeutically effective amount of compound of formula I classified in class 514, subclass 278 and 409. This election is made without traverse.

The Examiner also required election of a specific method of use and a single compound. Accordingly, Applicants elect the following method of use: malignant carcinoid and the following species: N, N-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine.

Upon entry of the present amendment, claims 11-12, and 21-38 are pending. Claims 21-38 are new. The new claims are fully supported by the specification and claims as originally filed. Claim 12 has been amended to further clarify the claim. Accordingly, no new matter has been added.

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that the pending claims are in condition for allowance. Such action is respectfully requested. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

for :  Reg # 57,972
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
One Financial Center
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Dated: February 7, 2007